D300e Digital Dispenser

Repetitive manual pipetting and tedious serial dilutions for drug discovery assays just became a thing of the past.With Tecan’s D300e Digital Dispenser, you can automatically dispense any volume into any well of any assay plate, quickly and easily. Simply add your liquid to the Dispensehead and let the instrument do the rest.

DISPENSING FEATURES / FLUID REQUIREMENTS / FLUID CLASSES / DIMENSIONS
T8+ Dispensehead Cassette
D4+ Dispensehead Cassette

Personalized treatments have the greatest potential to benefit cancer patients. Guided selection of the most suitable drug or combination of drugs for a specific patient’s cancer profile and genetics avoids a trial-and-error treatment strategy and minimizes collateral effects. In this eBook we have compiled examples of how Tecan’s benchtop solutions can support these workflows.

This application note describes the use of the D300e Digital Dispenser to prepare solutions of drug compounds at five different concentrations for subsequent target binding analysis using an interaction analyzer equipped with SPR.

The data presented in this application note demonstrates that the D300e can be used to miniaturize qPCR reactions to volumes as low as 2 μl and in addition offers greater process security and speed of the automated set-up.

The application note shows that the D300e is a suitable tool for qPCR set-up, offers significant sample, primer and reagent savings, and greatly reduces workflow time.

The data presented in this application note underlines the suitability of the D300e for protein-based assays.

The results generated with the D300 are consistent with an expertly performed manual process, but with the benefit of significant time savings and the elimination of serial dilution.

This technical note demonstrates, how easy it is to generate even the most complex plate layouts, like enzyme profiles, with the D300.

Brain tumors are the most common cause of mortality in childhood cancer patients, and treatment options are limited, especially for recurrent cases. Researchers at the University Hospital Düsseldorf are using automation to develop a more personalized approach to cancer medicine, performing rapid drug screening to identify novel therapeutic strategies to improve the chances of survival.

California-based company zPREDICTA™ has created a novel technology that reconstructs physiologically-relevant organ-specific human microenvironments that help eliminate the guesswork from drug development. Meaningful drug discovery studies involve complex experiments that are not feasible to perform manually. Automation is the answer, improving accuracy, saving time and reducing the amount of compound used.

Developing cancer drugs for clinical trials involves not only identifying and evaluating suitable agents, but also observing how they interact with the cocktail of other drugs in a cancer treatment regime. For the Telethon Kids Cancer Centre in Perth, Western Australia, increasing throughput and reducing assay volumes are essential to save money and time in the race to beat cancer.

The direct digital dispensing capabilities of the HP D300 are helping to identify potential new treatments for acute lymphoblastic leukemia at University Children’s Hospital Zurich. By enabling picoliter drug volumes to be dispensed straight into cell-based assay plates, the system is helping researchers to rapidly test novel drug combinations directly in patient-derived leukemia cells.

The HP D300 Digital Dispenser has enabled Translational Drug Development in the USA to automate its workflows, increasing sample throughput and the number of cell line panels handled, as well as enhancing workflow efficiency.

AstraZeneca scientists engaged in surface plasmon resonance studies are reaping the benefits of a recently acquired HP D300 Digital Dispenser, saving time, enhancing consistency and using significantly less compound for dose-response experiments.

Tecan has worked with promega to demonstrate the suitability of the Infinite® 200 PRO and HP D300 Digital Dispenser for real-time kinetic investigation of cytotoxicity using Promega’s CellTox™ Green Dye.

GlaxoSmithKline’s quest for improved anti-malarial treatments has been revolutionized by the speed and reliability of the HP D300 Digital Dispenser. This innovative system has increased throughput for standard drug titrations and enabled combinations of candidate compounds to be tested much more easily.

Symrise is using an HP D300 Digital Dispenser to improve throughput and reproducibility in its cell and molecular biology laboratories, offering more reproducible results for cosmetic active ingredient testing.

The Stanford genome Technology Center has invested in an HP D300 Digital Dispenser to study the effects of small molecule chemical inhibitors in yeast, enabling more experiments to be carried out more easily, and in less time.

TES Pharma is a specialist biotechnology company which performs molecular, cellular and ADME screening for drug discovery. The Company has recently purchased an HP D300 Digital Dispenser, and is now reaping the benefits of direct titration with improved assay reproducibility and more time to perform exploratory research.

In the last issue of the Tecan Journal, we announced the availability of the revolutionary HP D300 Digital Dispenser exclusively through Tecan’s Life Science Business. As customers in Europe and North America begin to place their orders, Kevin Peters, HP Global Sales Development Manager, reports on early customer experiences with the new technology.